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Abstract
Polycystic ovary syndrome (PCOS) is a variable disorder characterized by a broad spectrum of anomalies, including
hyperandrogenemia, insulin resistance, dyslipidemia, body adiposity, low-grade inflammation and increased cardiovascular
disease risks. Recently, a new polytherapy consisting of low-dose flutamide, metformin and pioglitazone in combination
with an estro-progestagen resulted in the regulation of endocrine clinical markers in young and non-obese PCOS women.
However, the metabolic processes involved in this phenotypic amelioration remain unidentified. In this work, we used NMR
and MS-based untargeted metabolomics to study serum samples of young non-obese PCOS women prior to and at the end
of a 30 months polytherapy receiving low-dose flutamide, metformin and pioglitazone in combination with an estro-
progestagen. Our results reveal that the treatment decreased the levels of oxidized LDL particles in serum, as well as
downstream metabolic oxidation products of LDL particles such as 9- and 13-HODE, azelaic acid and glutaric acid. In
contrast, the radiuses of small dense LDL and large HDL particles were substantially increased after the treatment. Clinical
and endocrine-metabolic markers were also monitored, showing that the level of HDL cholesterol was increased after the
treatment, whereas the level of androgens and the carotid intima-media thickness were reduced. Significantly, the
abundance of azelaic acid and the carotid intima-media thickness resulted in a high degree of correlation. Altogether, our
results reveal that this new polytherapy markedly reverts the oxidant status of untreated PCOS women, and potentially
improves the pro-atherosclerosis condition in these patients.
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Introduction
Hyperandrogenemia, insulin resistance, a state of low-grade
inflammation, body adiposity and a pro-atherogenic lipid profile
are usually present in adolescents and young women with
polycystic ovary syndrome (PCOS) [1,2,3]. Previous reports have
evidenced that the PCOS phenotype can also concur with primary
alterations of lipid metabolism involving increased levels of
oxidized LDL (oxLDL) particles [4,5,6]. Accordingly, PCOS
may accelerate the development of a cardiovascular-risk profile
even in the absence of clinical signs of atherosclerosis. Whether
this adverse pro-atherogenic profile and the enhanced oxidant
status may increase the risk for cardiovascular disease remains
unclear [7,8,9].
Most current pharmacological therapies are addressed to
ameliorate menstrual irregularities and cosmetic issues. There is a
clear need, however, for treatments that also improve endocrine-
metabolic markers associated with this disorder. Low-dose fluta-
mide (Flu, a pure androgen receptor blocker) and metformin (Met,
an insulin sensitizer) in combination with an estro-progestagen, is a
polytherapy that reduces total and abdominal fat, decreases the lean
mass deficit, and attenuates the abnormal pattern of adipokines in
young and non-obese PCOS women [1]. Recently, it has been
reported that the addition of low-dose pioglitazone (Pio, a PPARc
agonist) to the aforementioned polytherapy confers further
reductions of visceral fat and carotid intima-media thickness
(IMT), and increases further circulating high molecular-weight
(HMW) adiponectin [10,11,12,13]. Although the phenotypic
evidences demonstrate endocrine-metabolic improvements in a
wide spectrum of long-term health markers, the molecular
mechanisms underlying such polytherapy remain to be elucidated.
An approach to explore the metabolic changes in PCOS women
caused by this new treatment is metabolomics, defined as the
metabolic complement of functional genomics. Metabolomics
enables the characterization of endogenous small molecules that
serve as direct signatures of biochemical activity and therefore are
easier to correlate with phenotype. With the ultimate goal of the
comprehensive metabolome coverage, there is an overriding need
for analytical methodologies able to produce comprehensive
metabolite profiles from complex biological samples. However,
PLoS ONE | www.plosone.org 1 December 2011 | Volume 6 | Issue 12 | e29052due to the huge physico-chemical diversity of metabolites, there is
not a unique analytical technology able to cope with the whole
metabolome. Mass spectrometry (both GC-MS and LC-MS) and
NMR have demonstrated to be complementary analytical technol-
ogies in metabolomics-based studies [14,15,16], allowing to expand
the number of metabolites that can be comprehensively covered in
an untargeted experiment. Advantages and disadvantages of each
analytical technique and their current status in the field of
metabolomics are excellently reviewed elsewhere [17,18,19,20].
Here we present a longitudinal study to reveal the mechanism of
action of the low-dose Pio/Flu/Met polytherapy using metabo-
lomics. We analyzed using LC-MS, GC-MS and NMR-based
metabolomics serum samples of twelve young, non-obese women
diagnosed with PCOS, prior to and at the end of a 30 months
treatment with low-dose Pio/Flu/Met in combination with an oral
estro-progestagen. Our results show that at the end of the
treatment there are marked changes in the size of different
lipoprotein particles, in conjunction with downstream metabolic
oxidation products of LDL particles.
Methods
Participants
The study population consisted of twelve young, non-obese
women (age, 19.660.4 yr; BMI, 22.360.9 Kg/m2) diagnosed
with PCOS, participating in a randomized study [11], and whose
metabolomic profiles were assessed at baseline and after 30
months of treatment. Over 30 months, all women received the
same therapy for 24/28 days: pioglitazone (7.5 mg/d) at breakfast,
and metformin (850 mg/d), flutamide (62.5 mg/d) and a contra-
ceptive (ethinylestradiol 20 mg/d plus drospirenone 3 mg/d;
Yasminelle, Schering) at dinner time.
The inclusion criteria were: 1) hyperinsulinemia on a standard
2-h oral glucose tolerance test, defined as peak insulin levels
.150 U/mL and/or mean serum insulin .84 mU/mL; 2)
ovarian hyperandrogenism, as defined by each of the following
symptoms: hirsutism (Ferriman & Gallwey score .8); amenorrhea
(no menses for .3 months) or oligomenorrhea (duration of cycles
.45 days); biochemical androgen excess, as judged by circulating
androstenedione, total testosterone or free androgen index [FAI,
testosterone6100/sex hormone-binding globulin (SHBG)]; 17-
OH-progesterone hyperresponse (.160 ng/dL) to GnRH agonist
stimulation (leuprolide acetate 500 mg subcutaneously) [10].
The main exclusion criteria were: BMI ,17 Kg/m2 or
.29 Kg/m2; evidence of thyroid dysfunction; Cushing syndrome
or hyperprolactinemia; glucose intolerance; personal history of
diabetes mellitus; late-onset adrenal hyperplasia; abnormal liver or
kidney function; abnormal blood counts or serum electrolytes; and
treatment with an oral contraceptive or another medication
known to affect gonadal or adrenal function, carbohydrate or lipid
metabolism.
Patients were selected based on available serum samples pre-
and post-treatment. PCOS patients receiving placebo for 30
months did not meet ethical requirements and were not included
in the clinical study. Blood sampling was performed at baseline
and after 30 months on a cyclic off-treatment day (4/28 days). For
metabolomics analysis, serum samples (600 mL) were obtained
allowing plasma to clot at room temperature for 30 min. After
centrifugation at 4uC at 10,000 g for 10 min, samples were
maintained at 280uC until further analysis.
Experimental Procedures
Clinical and endocrine-metabolic variables, carotid IMT, body
composition [by dual-energy X-ray absorptiometry (DXA)] and
abdominal fat partitioning [by magnetic resonance imaging
(MRI)] were assessed prior to and at the end of the treatment as
previously described [9,10,11,12]. Sampling was performed in the
follicular phase of the cycle, or after 2 months of amenorrhea.
Hirsutism was graded according to the Ferriman and Gallwey
score [11]. Fasting blood glucose, serum insulin, LDL- and HDL-
cholesterol, sex hormone-binding globulin (SHBG), testosterone,
androstenedione and dehydroepiandrosterone-sulfate (DHEAS),
carotid IMT, body composition and abdominal fat partitioning
were measured as previously described [10,11,12,13].
Untargeted metabolomics analysis on serum samples was
performed using three different analytical platforms: NMR, GC/
MS and LC/ESI-MS TOF; each serum sample was split into three
aliquots and run in parallel using the three analytical platforms.
For the NMR measurement 300 mL of serum were mixed with
300 mL of phosphate buffer (0.75 mM Na2HPO4 adjusted at
pH 7.4, and 20% D2O to provide the field frequency lock). The
final solution was transferred to a 5 mm NMR tube and kept
refrigerated at 4uC in the autosampler until the analysis.
1H-NMR
spectra were recorded at 310 K on a Bruker Avance III 600
spectrometerH operating at a proton frequency of 600.20 MHz
using a 5 mm CPTCI triple resonance (
1H,
13C,
31P). Three
different
1H-NMR pulse experiments were performed for each
sample: 1) Nuclear Overhauser Effect Spectroscopy (NOESY)-
presaturation sequence to suppress the residual water peak; 2)
Carr-Purcell-Meiboom-Gill sequence (CPMG, spin-spin T2 re-
laxation filter) with a total time filter of 410 ms to attenuate the
signals of serum macro-molecules to a residual level; 20 ppm
spectral width and a total of 64 transients collected into 64 k data
points, and 3) Diffusion-edited pulse sequence with bipolar
gradients along with longitudinal eddy-current delay (LED) to
further estimate the serum lipoprotein profile according to our
recent described methodology [21].
The second aliquot was used for GC/MS analysis according to
Agilent’s specifications [22]. 100 mL of serum were spiked with
20 mL of internal standard solution (1 mg/mL succinic-d4 acid;
Sigma-Aldrich). After protein precipitation using 900 mL of cold
methanol/water (8:1 v/v) samples were centrifuged 10 minutes at
4uC, and 200 mL of the supernatant were spiked with 20 mLo f
myristic acid-d27 (Sigma Aldrich) used for retention time lock.
Samples were then lyophilized, and dissolved and incubated in
50 mL of methoxyamine in pyridine (0.3 mg/mL) during 16 hours
at room temperature. Derivatization by silylation reagents was
done using 30 mL of N-methyl-N-trimethylsilyltrifluoroacetamide
with 1% trimethylchlorosilane (MSTFA+1% TMCS, Sigma)
during 1 hour at room temperature. Samples were automatically
injected into a GC–MS system (HP 6890 Series gas chromato-
graph coupled to a mass selective detector model 5973) equipped
with a J&W Scientific DB 5-MS+DG stationary phase column
(30 m60.25 mm i.d., 0.1 mm film) (Agilent Technologies). The
injector temperature was set at 250uC, and the helium carrier flow
rate was kept constant at 1.1 mL/min. The column temperature
was held at 60uC for 1 min, then increased to 325uC at a rate of
10uC/min and held at 325uC for 10 min. The detector operated
in the electron impact ionization mode (70 eV) and mass spectra
were recorded after a solvent delay of 4 min with 2.46 scans per
second (mass scanning range of m/z 50–600; threshold abundance
value of 50 counts). The source temperature and quadrupole
temperature were 230 and 150uC, respectively.
The third aliquot was filtered through a 0.22 mm nylon
membrane filter and directly injected in a HPLC system (1200
series, Agilent Technologies) coupled to a time-of-flight (TOF)
mass spectometer (6210 Agilent Technologies) operated either in
positive (ESI+) or negative (ESI2) electrospray ionization in full
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C18, 2.6 mm, 15062.1 mm, 100 A (Phenomenex, Torrance, CA)
at a flow rate of 0.4 mL/min. The solvent system was: A=0,1%
formic acid in water; B=0,1% formic acid in acetonitrile (ACN).
The gradient profile started linearly from 2% to 20% buffer B in
3 min and was followed by another linear gradient from 20% to
100% buffer B in 18 min and hold for 7 min at 100% buffer B.
The injection volume was 15 mL. The instrument was set to
acquire over the m/z range 80–1000 with an acquisition rate of
1.3 spectra/second. MS/MS data of the metabolites of interest
was collected using an HPLC-ESI QqQ system (6410, Agilent
Technologies) using identical LC conditions.
Quality control samples (QCs) consisting of pooled serum
samples of all patients entering the study were used. In our LC-MS
platform, QCs were injected before the first study samples were
analyzed and then periodically after 5-study samples. For GC-MS,
QCs were injected periodically after 10-study samples. In addition,
to begin with the chromatographic analysis, injection of 3 blank
runs were performed both in LC/MS and GC/MS. Furthermore,
samples entering the study were entirely randomized to reduce
systematic error associated with instrumental drift.
Ethics
This clinical study was registered as ISRCTN12871246 and
conducted in Sant Joan de De ´u University Hospital (Barcelona,
Spain), without support from industry, after approval by the
Institutional Review Board of Sant Joan de De ´u University
Hospital, and after written informed consent by each patient.
Data analysis and statistical methods
The acquired CPMG NMR spectra were phased, baseline-
corrected and referenced to the chemical shift of the a-glucose
anomeric proton doublet at 5.22 ppm. Pure compound refer-
ences in BBioref AMIX (Bruker); HMDB and Chenomx
databases were used for metabolite identification. After baseline
correction, intensities of each
1H-NMR regions identified in the
CPMG 1D-NMR spectra were integrated for each sample
entering the study using the AMIX 3.8 software package (Bruker,
GmBH). To identify discriminating markers, intensities of each of
the identified spectral regions in the untreated PCOS serum
spectra were compared against the same spectral regions on their
treated counterparts using principal component analysis (PCA) of
the auto-scaled within-subject variation dataset derived from
multilevel simultaneous component analysis (MSCA) [23] and the
non-parametric Wilcoxon-rank summed test. LC/MS (ESI+ and
ESI2 mode) and GC/MS data were processed using the XCMS
software [24] (version 1.6.1) to detect and align features. A
feature is defined as a molecular entity with a unique m/z and a
specific retention time. XCMS analysis of these data provided a
matrix containing the retention time, m/z value, and integrated
peak area of each feature for every serum sample extraction
discussed above. The tab-separated text files containing GC/MS
data were imported into Matlab where normalization to internal
standard succinic acid-d4 was also performed. QCs were always
projected in a PCA model together with the study samples to
verify that technical issues do not mask biological information.
Basal PCOS samples and their treated counterparts were
compared using the integrated peak area of each feature via
PCA of the auto-scaled within-subject variation dataset derived
from MSCA and the non-parametric Wilcoxon-rank summed
test, and assigning a fold value to indicate the level of differential
regulation due to the 30-months treatment. Differentially
regulated metabolites (fold.2) that were statistically significant
(p,0,05) detected by LC/MS were characterized by MS/MS
using a LC-QqQ instrument. Differentially regulated metabolites
detected by GC/MS were identified using the NIST and Fiehn
mass spectral libraries. In addition, the retention time of pure
standards were confirmed. Data (pre-) processing, data analysis,
and statistical calculations were performed in Matlab (Matlab
version 6.5.1, Release 13). The MSCA matlab code was
downloaded and adapted from www.bdagroup.nl.
Results
Low-dose Pio/Flut/Met polytherapy improves
biochemical long-term health markers in PCOS patients
A series of biochemical parameters were initially monitored in
PCOS patients prior to and at the end of the 30 months treatment.
The results summarized in Table 1 indicate that the treatment
caused a broad spectrum of biochemical adjustments, including a
marked reduction in serum concentrations of androgens such as
testosterone (24169%, p=0.0026) and androstenedione
(23565%; p=0.003), whereas insignificant changes in body
weight were measured. The carotid IMT was markedly reduced
(23363%; p=3.0610
25) after the treatment, and it was
accompanied by a significant augment of HDL cholesterol levels
in serum (3465%, p=0.005). In addition, some PCOS patients
decreased their visceral fat mass considerably after the treatment.
Of note, markers of liver dysfunction such as transaminases and
lactate dehydrogenase remained unaltered (data not shown).
Overall, these changes are clinically associated with a phenotypic
improvement in PCOS patients after the treatment, and
complement the metabolomic analysis.
Multivariate Data Analysis of PCOS Serum Samples
Given the longitudinal nature of our study, we used a
multilevel simultaneous component analysis (MSCA) method
[23] to examine independently different types of variation in the
NMR and MS-based metabolomic data, namely, variation
between patients and variation in time within patients as a result
of the polytherapy. MSCA enables to split the variation within-
subjects that accounts for the variation before and after the
treatment for each patient, from the variation between-subjects
that accounts for the biological variation (i.e., genotype
differences) in two different data matrices. The variation
within-subjects is represented in the PCA plot of Figure 1. The
PC1/PC2 scores plot of the
1H-NMR CPMG spin-echo
experiment shown in Figure 1A reveals a clear clustering along
PC1 (,57% of the variance), which accounts for the post-
treatment variation of each patient. Figure 1B depicts the bar
loading plot for PC1, the higher the absolute bar value the higher
the influence of such variable in the variation induced by the
treatment. Hence, PCOS serum samples at the end of the
treatment were characterized by rather larger values of choline-
containing molecules and diminished values of 1,2-propanediol
and lysine, among others. Similar PC1/PC2 scores plot was
observed with the GC/MS and LC/MS derived data (Figure 1C
and Figure 1F), confirming a profound metabolic variation within
patients due to the 30 months polytherapy. Loadings bar plot
were also studied and some of the features implicated in this
variation were depicted as boxplots in Figures 1D–H. Altogether
our MSCA model set apart the biological variation between
patients and highlighted within-patient variation due to the Pio/
Flu/Met polytherapy, showing clear differences in the relative
concentration of specific compounds in the serum of PCOS
patients. Accordingly, we focused in the characterization of the
most discriminating compounds of the MSCA model.
Metabolomic Study of a New Polytherapy for PCOS
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1H-NMR spectra
The CPMG
1H NMR serum spectra are composed of
overlapped resonances from low molecular weight metabolites
such as amino acids or lactate and T2 lipoprotein attenuated
signals. Figure 2A depicts representative CPMG
1H NMR spectra
of a PCOS patient’s serum prior to and at the end to the 30
months Pio/Flu/Met polytherapy. Clear differences can be
observed between the same serum sample prior to and after the
30 months treatment. The polytherapy induced lipoprotein
rearrangements reflected in resonances attributable to both
methylene (d 1.25 ppm) and methyl (d 0.85 ppm) terminal groups
of fatty acids contained in LDL and VLDL particles. In contrast, a
depletion of the 1,2-propanediol doublet at 1.14 ppm and the
acetate broad singlet arising at 1.91 ppm was observed after the
treatment. Also, two prominent unidentified resonances arisen in
the serum spectra of PCOS patients prior to the treatment were
decreased as a result of the polytherapy. The first resonance
corresponded to a broad singlet (multiplicity examined by 2D J-
res) at 0.85 ppm, and the second unknown resonance was
composed of three different peaks centered at 1.18 ppm which
probably do not correspond with a triplet signal because their
intensities did not match exactly with the established 1:2:1 triplet
intensity ratio.
Table 2 summarizes the statistical values, detailed moieties
assignments and structural identities of the metabolites analyzed
using CPMG
1H NMR. The relative concentration of glutamate,
1,2-propanediol, lysine, and succinate in serum samples was
markedly decreased as a result of the treatment. In contrast,
NMR signals attributed to N-(CH3)3 groups of choline-containing
molecules were increased after the treatment. In addition, the
three unknown NMR signals centered at 1.18 ppm, which match
the characteristic pattern of resonances found in the serum
spectra of patients with coronary heart disease (CHD) reported
by Jankowski et al. [25], decreased in the spectra after the
treatment. Such specific pattern of resonances corresponded to
oxidized LDL particles, as demonstrated by Jankowski and co-
workers when they compared the spectrum of lipoprotein
subfractions of patients with CHD and LDL particles oxidized
in vitro using Cu
2+. To confirm the association of lipoprotein
particles with these signals we precipitated serum proteins from
untreated patients using cold-acetone and recorded the
1H-NMR
spectra on the supernatant. As showed in Figure 2B, the three
signals centered at 1.18 ppm disappeared after cold acetone
precipitation, suggesting an association with lipoprotein-related
particles. Overall, our results suggest that the Pio/Flu/Met
polytherapy has a dramatic effect on the lipoprotein profile of
PCOS patients.
Lipoprotein rearrangements after low-dose Pio/Flu/Met
intervention
To confirm that the lipoprotein profile is severely affected by the
Pio/Flu/Met treatment, we measured the size of lipoprotein
particles in serum samples prior to and at the end of the 30 months
intervention, according to our recently described methodology
[21]. In brief, the size of different lipoprotein subclasses were
estimated using up to seven Lorentzian functions to fit the methyl
peak surface obtained from 2D (bipolar-LED) diffusion edited
1H-
NMR experiments. Then, diffusion coefficients and hydrodynamic
radius through Stokes-Einstein equation for each one of these
seven functions were estimated. Figure 3A shows the average
methyl spectrum centered at 0.85 ppm after 30 months of
polytherapy in relation to the average signal at baseline. The shift
to the upfield region in the spectra after the treatment indicates a
greater contribution of the HDL subfraction to the signal of
methyl groups. Figure 3B shows the fitted spectrum of a treated
PCOS patient using the seven Lorentzian functions. Based on the
previously measured diffusion coefficients described in our
methodology [21], we estimated the hydrodynamic radius (i.e.,
size) for each of these functions. Figure 3C shows the mean
percentage of variation of the estimated radius for each function as
Table 1. Endocrine-metabolic markers, carotid IMT and abdominal fat partitioning at baseline and after 30 months of low dose
Pio/Flu/Met polytherapy.
At baseline (N=12) At 30 months (N=12) p-values
Age (yr) 19.860.4 -
BMI (Kg/m
2)2 2 . 3 61 22.561.1 0.9770
Score F&G 16.161.3 860.6 0.0001
Total cholesterol (mg/dL) 165.367.1 18568.1 0.0606
HDL-cholesterol (mg/dL) 50.862.2 68.464.2 0.0055
LDL-cholesterol (mg/dL) 102.366.1 96.965.4 0.7726
Triglycerides (mg/dL) 64.465.3 97.769.7 0.0093
Testosterone (ng/dL) 77.266 43.966.6 0.0026
SHBG (nmol/L) 37.863.8 164.368.6 4.0610
25
FAI 8.561.8 0.960.2 4.0610
25
Androstendione (ng/dL) 444.3647 276625 0.0030
DHEAS (mg/dL) 265637 202633 0.2365
Carotid IMT (mm) 0.4660.02 0.3160.01 3.0610
25
Subcutaneus (Sc) fat mass (cm
2)1 4 4 650 151623 0.8852
Visceral (Vis) fat mass (cm
2)6 8 617 4068 0.0783
Vis/Sc fat mass 0.3960.04 0.2060.04 0.1484
Values are mean 6 SEM; BMI, body mass index; SHBG, sex hormone-binding globulin; DHEAS, dehydroepiandrosterone-sulfate; FAI, free androgen index; IMT, Intima-
Media Thickness.
doi:10.1371/journal.pone.0029052.t001
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1N-NMR, GC/MS and LC/ESI-TOF MS data. (A) PC1/PC2 scatter scores plot and (B) PC1 loading bar plot
of PCA calculated on the within-subject matrix derived from the MSCA modelling of the 32 selected spectral regions identified in the
1H-NMR CPMG
serum spectra of untreated (red markers) and treated (green markers) PCOS patients. (C) PC1/PC2 scatter scores plot of PCA calculated on the within-
subject matrix derived from the MSCA modelling of GC/MS data. Boxplots of (D) azelaic acid and (E) 1,2-proanediol, the two metabolites
corresponding to the most discriminating features along the corresponding PC1 loadings bar plot. (F) PC1/PC2 scatter scores plot of PCA calculated
on the within-subject matrix derived from the MSCA modelling of LC/ESI-TOF MS data. Boxplots of (G) 9- and 13-HODE, and (H) caprylic acid, the two
metabolites corresponding to the most discriminating features along the PC1 loadings bar plot. P-values derived from Wilcoxon rank-summed pair-
matched comparison of untreated and treated PCOS patients. Mean 6 sem of the percentage of variation are also indicated.
doi:10.1371/journal.pone.0029052.g001
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significantly increased radiuses associated with atherogenic small,
dense LDL (F3) and protective large HDL (F4–F6) lipoprotein
subclasses.
Mass spectrometry analysis
Our mass spectrometry-based platform involves LC-ESI-
TOF-MS and GC-single quad MS profiling followed by data
analysis with the open-source software XCMS. The relative
Figure 2. CPMG
1H NMR spectra of a representative PCOS patient’s serum. (A) Comparative spectra at baseline and after 30 months of Pio/
Flu/Met polytherapy. CPMG spin echo experiment allows filtering broad signals of lipid and lipoproteins enhancing low-molecular weight
metabolites such as amino acids, lactate and intermediate metabolites. The inset displays an expanded d (0.75–1.5 ppm) spectral region showing two
unidentified resonances characteristic of the serum spectra of untreated PCOS patients: a broad singlet arising at 0.85 ppm and three peaks centered
at 1.18 ppm. (B) CPMG
1H-NMR spectra of the same untreated PCOS patient shown in Figure 2A before and after cold acetone precipitation. After
acetone precipitation the three signals centered at 1.18 ppm were depleted, confirming the occurrence of oxidized lipoprotein-related structures in
the serum of PCOS women.
doi:10.1371/journal.pone.0029052.g002
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by comparing the integrated area of each feature, and
calculating the percentage of variation of such feature to indicate
the level of differential regulation prior to and at the end of the
Pio/Flu/Met intervention. Some of the most up-regulated
metabolites were identified by tandem MS/MS. Metabolite
annotations and statistical analysis are summarized in Table 2.
Metabolites identified using GC/MS were consistent with
NMR data. For example, the levels of glutamate and 1,2-
propanediol in serum were also significantly decreased after
the polytherapy. In addition, the treatment led to decreased
levels of nonanoic, glutaric and azelaic acid. Of note, the
level of azelaic acid resulted positively correlated with carotid
IMT (r=0.92, p=3.96610
27) (Figure 4). LC/MS data
showed that the treatment resulted in significantly increased
level of caprylic acid, whereas it induced a marked reduction in
the level of 9-HODE and 13-HODE, the most abundant mono-
hydroxyderivative forms resulting from the oxidation of linoleic
acid.
Discussion
The underlying causes of PCOS are still unknown, and
therefore the medical treatment is tailored to the patient’s
symptoms. Typically, these are lowering insulin level, restoration
of fertility and regular menstruation, and treatment of hirsutism
and acne. General interventions such as low-dose flutamide,
metformin and pioglitazone in combination with an estro-
progestagen can be very beneficial because it confers further
improvements of the endocrine-metabolic state. Our metabo-
lomic analysis has revealed that the polytherapy induces an
increase in the estimated radius of small, dense LDL lipoprotein
subclasses together with a reduction in the level of oxidized
LDL particles. These macromolecular rearrangements are
associated with changes in the level of specific downstream
metabolites produced by linoleic acid peroxidation (i.e. 9-
HODE, 13-HODE). Linoleic acid represents the most abundant
polyunsaturated fatty acid in LDL particles. Oxidation of LDL
transforms linoleic acid into different hydroperoxyderivative
Table 2. Summary of the metabolites found to be significantly varied in either analytical platform after 30 months low-dose Pio-
Flu-Met polytherapy.
1H-NMR analysis (N=12)
Metabolite d(ppm) multiplicity p-values Mean (%Variation) ±SEM Moieties assignments Comments
unknown* 0.85 s (broad) 0.0038 235619 - *oxLDL related structures
1,2-propanediol 1.14 d (6.5 Hz) 0.0010 265627 2(-CH3-)
unknown* 1.18 36s 0.0097 224627 - *oxLDL related structures
Lysine 1.69 m 0.0008 24564 d-CH2
Acetates 1.91 s 0.0008 25566C H 3
Glutamate 2.35 m 0.0008 25464 c-CH2
Succinate 1.76 s 0.0008 24265 2 (-CH2-)
Cholines-containing
molecules
3.21 s 0.0149 120622 N-(CH3)3
unknown 3.35 s 0.0010 156641 -
unknown 3.38 s (broad) 0.0010 23565-
unknown* 3.65 m 0.0074 234610 - *oxLDL related structures
GC-MS analysis (N=6)
Metabolite m/z ion RT(min) p-values Mean (%Variation) ±SEM EI-confirmatory m/z ions
1,2-propanediol
1 117 6.05 0.0069 277617 -
Nonanoic acid 215 11.15 0.0069 26867-
Glutaric acid
1 261 11.75 0.0421 29166-
Glutamate 186 13.37 0.0037 25869 56,84
Azelaic acid
1 317 16.38 0.0021 29664 124,152,125,201,199,107,317,129,318,183,
111,204,75,97,153,55,67,185,197,81,123,171
LC/ESI-TOF MS analysis (N=9)
Metabolite [M-H]
2 RT(min) p-values Mean (%Variation) ±SEM [M] Formula d(ppm) MS/MS diagnostic ions
Caprylic acid 143.1068 23.2 0.0143 183613 144.1141 C8H16O2 6 143@20eV
9/13-HODE 295.2282 8.7 0.0143 28667 296.2357 C18H32O3 1 295,277,195@20eV
d=doublet, s=singlet, m=multiplet. Percentage of variation was calculated for each patient as the area of the spectral region or selected XCMS feature at baseline
minus the area of the same feature or spectral region after the treatment relative to the former. Values are expressed as mean 6 SEM. A negative value indicates that
levels of the corresponding metabolite resulted significantly decreased with the treatment while positive values indicate a significant increase. p-values correspond to
Wilcoxon rank-summed test and FDR correction. Statistical significance was considered for those spectral regions or features having p-corrected values,0.05 and fold
changes.2;
1Indicates those metabolites whose retention time and mass spectra were checked using pure standard references.
doi:10.1371/journal.pone.0029052.t002
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and released by specific lipases from the membrane lipids as
free hydroxyoctadecadienoic acid (HODE), such as 9- and 13-
HODE, identified in our study [27] (Figure 5). In addition, the
oxidative modification and degradation of fatty acids contained in
LDL particles generates a complex array of shorter chain-length
fragments that covalently modify e-amino groups of lysine
residues of the protein moiety to generate the oxidatively modified
LDL particles [28,29,30]. Among these shorter chain-length
fragments causing structural modifications of proteins, we have
identified azelaic acid and glutaric acid [31]. It is worth mentioning
that azelaoyl phosphatidylcholine (azPC) accounts for almost
two-thirds of the oxidized phospholipids in oxLDL [32,33]. Also,
accumulation of azelaic acid and glutaric acid in plasma of diabetic
rat models and type 1 diabetic patients, respectively, has been
reported previously [34], Overall, our NMR- and MS-
based metabolomics study demonstrate that the Pio/Flu/Met
polytherapy reduces the amount of oxidized lipoprotein particles
and downstream oxidative metabolites in the serum of PCOS
patients.
Previous studies explored the effect of flutamide, metformin,
and pioglitazone in monotherapy or in combination therapy. For
example, combined Pio/Met therapy in type 2 diabetic patients
improved their specific lipid abnormalities [35,36,37,38]. Piogli-
tazone, when used both in monotherapy or in combination
therapy, modifies the atherogenic lipoprotein profile reducing
triglycerides, increasing the larger HDL2 subfractions and
improving the HDL cholesterol load [39]. Very few studies,
however, have addressed in detail the effects of pioglitazone and
metformin in LDL subfractions. Lawrence et al [40] reported a
significant fall in LDL3 mass and LDL3 proportion in overweight
type 2 diabetic patients treated with metformin alone. The total
cholesterol–to–apoB ratio (used as a surrogate marker for changes
in LDL subfraction distribution), however, remained unchanged.
In contrast, when overweight type 2 diabetic patients were treated
with pioglitazone alone, a significant increase in the cholesterol-to-
Figure 3. Lipoprotein
1H-NMR analysis. (A) Comparative bipolar-LED diffusion mean spectra of the methyl region (d 0.85 ppm) for untreated
and treated PCOS patients. (B) Bipolar LED pulse sequence
1H NMR spectra of a treated PCOS serum showing the fitting of the methyl band using the
seven Lorentzian functions derived from our previously described methodology. Black line represents the original methyl envelope and green line the
reconstructed spectrum after the fitting. (C) The estimated radiuses of lipoprotein particles in serum calculated using the seven Lorentzian functions
were compared at baseline and after 30 months of Pio/Flu/Met polytherapy.
doi:10.1371/journal.pone.0029052.g003
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atherogenic) LDL particles. Pioglitazone alone also induced an
increase of LDL particles diameter and a decrease in LDL density
in normolipidemic, nondiabetic patients with hypertension [41].
Finally, the treatment of Goto-Kakizaki rats (a type 2 diabetes
model) with pioglitazone reduced the levels of lipid peroxides in
plasma and the susceptibility of LDL particles to oxidation [42].
Our findings result in good agreement with previous studies and
evidence that the addition of pioglitazone to the combined
flutamide/metformin polytherapy induces an increase in the mean
diameter particles of small LDL subfractions. Besides, our
comprehensive metabolomic approach allowed us not only to
detect changes in the size of the different lipoprotein particles but
also in downstream, oxidation products such as 9- and 13-HODE,
azelaic acid and glutaric acid. Overall, our results demonstrate the
utility of metabolomics to explore the effect of medical treatments
on metabolic alterations. In this study, the combined pioglitazone/
flutamide/metformin polytherapy reverses the oxidant status of
untreated PCOS patients. Given that oxidation of LDL particles
has been suggested to be the key triggering event in the
progression of atherosclerotic lesions [43], and that the carotid
IMT is also markedly reduced after 30 months of polytherapy, we
postulate that untreated young PCOS women may suffer early
stages of atherosclerosis that could potentially have deleterious
effects at older ages. Besides, we have demonstrated that azelaic
acid levels are strongly correlated with carotid IMT. Hence we
suggest that azelaic acid can be considered as an early marker of
lipoprotein oxidation and subclinical atherosclerosis.
Figure 4. Correlation between IMT and azelaic acid levels in
serum. Positive significant correlation (r=0.92, p=3.96610
27) be-
tween carotid IMT values and azelaic acid levels. Azelaic acid levels were
calculated as the ratio of the fragmentation peak of azelaic acid at m/
z=317 (retention time=16.38 min) and the peak area of the internal
standard. Red and green dots represent values of untreated and treated
PCOS patients respectively.
doi:10.1371/journal.pone.0029052.g004
Figure 5. Linoleic acid oxidation products. Formation of linoleic acid hydroperoxyderivatives (HPODEs) are further reduced to their
corresponding hydroxyderivatives (HODES). Chemical structures of linoleic acid (18:2); 9- and 13-hydroperoxylinoleic acid (9- and 13-HPODE); and9
and 13-hydroxylinoleic acid (9- and 13-HODE).
doi:10.1371/journal.pone.0029052.g005
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